Your Unread Messages
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Serum amyloid A and C-reactive protein concentrations are differently associated with markers of autoimmunity in patients with primary Sjogren's syndrome
Journal of Rheumatology, 10/19/09
Pertovaara M et al. – Primary Sjögren’s syndrome (pSS) is an autoimmune disease in which the concentration of the acute-phase protein serum C-reactive protein (CRP) is low. We investigated whether levels of another acute-phase protein, serum amyloid A (SAA), are increased in patients with pSS and whether the immunological markers in patients with pSS are associated with variation in SAA levels. Results imply that high SAA production could constitute a protective element in pSS: high SAA levels inhibit in particular various signs of B cell hyperreactivity, i.e., IgG and autoantibody production
Methods- Serum SAA concentrations measured by ELISA in 74 patients with pSS and 56 control subjects with sicca symptoms
- Median SAA levels did not differ significantly between patients with pSS and subjects with sicca symptoms
- In pSS SAA concentrations correlated significantly with age, leukocyte count, CRP, interleukin 6, and C4
- Unlike CRP, there was significant inverse correlation between SAA and serum IgG levels and anti-SSA antibody titers, as well as trend towards inverse correlation between SAA and antinuclear antibody and rheumatoid factor titers
Today in Autoimmune/Heritable...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögrens syndrome
Arthritis & Rheumatism, 11/06/09
Lung involvement in patients with primary Sjögrens syndrome: What are the predictors?
Rheumatology International, 10/26/09
A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
Rheumatology, 10/23/09
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Hepatoprotective effect of TNF-alpha blockade in psoriatic arthritis: A cross-sectional study
Annals of Rheumatic Diseases, 11/09/09
Musculoskeletal manifestations in patients with malignant disease
Clinical Rheumatology, 11/13/09
The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study
Arthritis & Rheumatism, 11/04/09
Today in Connective Tissue Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Nephrogenic systemic fibrosis
Current Opinion in Rheumatology, 11/04/09
A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
Rheumatology, 10/23/09
Comparison of injection methods in myofascial pain syndrome: A randomized controlled trial
Clinical Rheumatology, 10/27/09
Sponsor
Article Search
Sponsor


See All



